Castle Biosciences stock fell 8.98 percent after insider selling

Published on 10/07/2026 at 01:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Castle Biosciences stock traded at USD 33.36 on October 6, 2026, with a USD 1.0 billion market cap. Q2 revenue reached USD 99.86 million against USD 86.23 million.

CSTL, US14843C1053, Illustration mit AI erstellt.

Castle Biosciences stock (ISIN US14843C1053) fell 8.98 percent to USD 33.36 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. The decline followed reported insider selling, while the company continues to post quarterly revenue above analyst expectations.

Insider sale meets strong revenue

As MarketBeat reported on October 6, 2026, Castle Biosciences shares came under pressure after Chief Operating Officer Kristen Oelschlager sold 4,153 shares for USD 149,300.35 in a transaction executed under a pre-arranged Rule 10b5-1 plan.

The same report identified a USD 36.65 prior close and a trading low of USD 34.48 during the session. The structured quote for the completed session showed a USD 33.36 last price, a USD 33.10 day low, a USD 37.61 day high and volume of 607,645 shares.

Quarterly beat supports the case

Castle Biosciences reported USD 99.86 million in quarterly revenue for the period ended June 30, 2026, compared with an USD 86.23 million consensus estimate, according to MarketBeat. Adjusted EPS was negative USD 0.07 against a consensus loss of USD 0.41, a USD 0.34 improvement versus expectations.

The operating picture is therefore mixed rather than purely price-driven. Castle Biosciences posted a GAAP net loss of USD 2.06 million in the second quarter, while operating cash flow reached USD 15.20 million for the same period. Its diagnostics portfolio serves dermatology and gastroenterology, including tests designed to assess cancer risk and guide treatment decisions.

Analysts see upside to USD 42

MarketBeat reported on October 6, 2026, that 10 analysts covered Castle Biosciences with one Strong Buy, seven Buy, one Hold and one Sell rating. The resulting consensus was Moderate Buy with an average price target of USD 42.00, which lies 25.9 percent above the USD 33.36 session price.

The valuation reference remains wide: the stock's 52-week range was USD 17.72 to USD 44.28 on October 6, 2026. Castle Biosciences had a market capitalization of USD 1.0 billion, placing the revenue beat against a company whose annual market value is more than ten times its latest quarterly sales.

Castle Biosciences stock stays below its yearly high

Castle Biosciences stock was last at USD 33.36 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, below its 52-week high of USD 44.28 and above its 52-week low of USD 17.72. The next signal for investors is whether quarterly revenue growth can translate into sustained profitability.